Гликлазид Drug photo

The description is actual on 12.04.2016

  • Latin name: Gliclazide
  • ATH code: A10BB09
  • Active ingredient: Gliklazid
  • Producer: Ozone of Ltd company (Russia)


In 1 tablet of 80 mg of a gliklazid.

Gipromelloza, cellulose microcrystallic, magnesium silicon stearate dioxide as excipients.

In 1 tablet of Gliklazid of MV of 30 mg. gliklazida.

Release form


Pharmacological action


Pharmacodynamics and pharmacokinetics


The hypoglycemic means which is to derivatives of a sulfonilmochevina of the II generation. Stimulates production of insulin with β-cells and recovers a physiological profile it. Administration of drug reduces time from the meal moment prior to insulin secretion as recovers the first (early) phase of secretion and strengthens the second phase. Reduces peak of increase of sugar after meal. Increases sensitivity of fabrics to insulin.
In addition, reduces risk of thromboses, suppressing aggregation and adhesion of thrombocytes, recovering a physiological pristenochny fibrinolysis, improves microcirculation. This effect is important as it allows to reduce risk of terrible complication — a retinopathy and a mikroangiopatiya. At a diabetic nephropathy decrease in a proteinuria against treatment is noted by this drug. Interferes with development of atherosclerosis as possesses anti-atherogenous properties.

Gliklazid MV provide to feature of a dosage form effective medical concentration and control of level of glucose within 24 hours.


High is quickly soaked up in a gastrointestinal tract, extent of absorption. The maximum concentration (at reception of 80 mg) is defined by 4 h. Communication with proteins to 97%. Equilibrium concentration is reached after reception within 2 days. It is metabolized in a liver to 8 metabolites. To 70% intestines — 12% are removed by kidneys. The elimination half-life of a usual gliklazid makes 8 hours, prolonged till 20 o'clock.

Indications to use


  • insulin-dependent diabetes mellitus;
  • ketoacidosis;
  • diabetic coma;
  • heavy dysfunctions of kidneys / liver;
  • inborn lactose intolerance, sprue;
  • concomitant use with Danazol or Phenylbutazone;
  • age till 18 flyings;
  • hypersensitivity;
  • pregnancy, lactation.

With care it is appointed at advanced age, at irregular food, a hypothyroidism, a hypopituitarism, a heavy current of an ischemic heart disease and the expressed atherosclerosis, adrenal insufficiency, long treatment glucocorticosteroids.

Side effects

  • nausea, vomiting, stomach aches;
  • thrombocytopenia, erythropenia, agranulocytosis, hemolitic anemia;
  • allergic vasculitis;
  • skin rash, itch;
  • liver failure;
  • vision disorder;
  • hypoglycemia (at overdose).

Gliklazid, application instruction (Way and dosage)

Tablets Gliklazid appoint 80 mg in an initial daily dose, accept 2 times a day in 30 minutes prior to food. Further the dose is adjusted, and average daily makes 160 mg, and the maximum 320 mg. With usual release Gliklazid MB can notice tablets. The possibility of replacement and a dose are defined in that case by the doctor.

Gliklazid MB 30 mg accept during a breakfast once a day. Change of a dose is undertaken after 2 weeks of treatment. It can make 90 - 120 mg.

At the admission of reception of tablets it is impossible to accept a double dose. When replacing other glucose-lowering drug to these the transition period is not required — it begins to be accepted next day. The combination to guanyl guanidines, insulin, alpha glucosidase inhibitors is possible. At easy and average degree of a renal failure it is appointed in the same doses. At patients of risk group of a hypoglycemia use the minimum dose.


Overdose is shown by hypoglycemia symptoms: a headache, fatigue, sharp weakness, sweating, heartbeat, increase of the ABP, arrhythmia, drowsiness, agitation, aggression, irritability, the slowed-down reaction, a vision disorder and speeches, a tremor, dizziness, spasms, bradycardia, a loss of consciousness.

At moderately expressed hypoglycemia without disturbance of consciousness reduce a dose of drug or increase amount of the carbohydrates arriving with food.

At serious hypoglycemic conditions immediate hospitalization and assistance is necessary: in/in struyno 50 ml of 20-30% of solution of glucose, then kapelno 10% solution of a dextrose or glucose. Within two days glucose level is controlled. The dialysis is inefficient.


Simultaneous use with Cimetidinum which increases concentration of a gliklazid that can entail a heavy hypoglycemia is not recommended.

At use with Verapamil it is necessary to control glucose level.

Hypoglycemic action is exponentiated at use with the salicylates derivative of Pyrazyl ketone, streptocides, caffeine, Phenylbutazone, Theophylline.

Use of non-selective beta adrenoblockers increases risk of a hypoglycemia.

At Akarboza's use the additive hypoglycemic action is noted.

At use of GKS (including outside forms of use), barbiturates, diuretics, estrogen and progestins, Difenina, Rifampicin decreases sakharosnizhayushchy effect of drug.

Terms of sale

According to the recipe.

Storage conditions

At a temperature no more than 25 Pages.

Period of validity

3 years.

Gliklazid's analogs

Coincidence on the ATH code of the 4th level:

Glidiab of MV, Gliklazid-Akos, Diabinaks, Diabeton of MV, Diabetalong, Glyukostabil.

About Gliklazida

Now apply more widely derivative sulfonilmochevina of the II generation which Gliklazid because they exceed drugs of the previous generation on expressiveness of hypoglycemic action as affinity to receptors of β-cells is 2-5 times higher that allows to reach effect at purpose of the minimum doses treats. This generation of drugs causes side effects less often.

Feature of drug is that at its metabolic changes several metabolites are formed, and one of them exerts considerable impact on microcirculation. Many researches proved decrease in risk of microvascular complications (retinopathies and a nephropathy) at treatment gliklazidy. Expressiveness of angiopatiya decreases, food of a conjunctiva improves, disappears vascular staz. For this reason it is appointed at complications of a diabetes mellitus (an angiopatiya, a nephropathy from initial HPN, a retinopathy) and patients who for this reason were transferred to reception of this drug report about it.

Many focus attention that a pill needs to be taken after a breakfast which contains enough carbohydrates, starvation during the day is not admissible. Otherwise, against a low-calorie diet and after an intensive exercise stress development of a hypoglycemia is possible. At a physical overstrain it is necessary to change a drug dose. At some persons after alcohol intake hypoglycemic states were also noted.

Elderly people as the risk of development of a hypoglycemia at them is increased are especially sensitive to hypoglycemic drugs. In this connection it is better for them to use short-range drugs (usual gliklazid).
Patients note convenience of use of tablets of the modified release in the responses: have effect slowly and evenly therefore they are applied once a day. Besides, the effective dose is twice less than it, than a dose of a usual gliklazid.

There are messages that in several years (from 3 to 5 since the beginning of reception) resistance — decrease or lack of effect of drug developed. In such cases the doctor selected combinations of other sakharosnizhayushchy means.


  • Gliklazid of MV of 30 mg No. 60 of a tablet with the Ltd company modified vysvobozhdeniyemozon
to show still


  • Gliklazid No. 30 Health tablet 0.08 (Ukraine, Kharkiv)


  • Gliklazid of 80 mg No. 60 of the tab. Himfarm (Kazakhstan)
  • Gliklazid of 80 mg No. 60 of the tab. Global Farm of JV LLP (Kazakhstan)
to show still
Section: Diabetic
in more detail

Education: Graduated from Sverdlovsk medical school (1968 - 1971) as "Paramedic". Graduated from the Donetsk medical institute (1975 - 1981) as "An epidemiologist, a hygienist". Passed postgraduate study in the Central scientific research institute of epidemiology Moscow (1986 - 1989). An academic degree – the candidate of medical sciences (degree is awarded in 1989, protection – the Central scientific research institute of epidemiology Moscow). Numerous advanced training courses are studied in epidemiology and infectious diseases.

Experience: Work as the manager of department of disinfection and sterilization of 1981 - 1992. Work as the manager of department of especially dangerous infections of 1992 - 2010. Teaching activity at Medical institute 2010 - 2013.

PAY ATTENTION! Information on drugs on the website is help generalizing, collected from public sources and can form the basis for making decision on use of medicines it is not aware of treatment. Before medicine use Gliklazid surely consult with the attending physician.